Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Clancy

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
The Journal of Biological Chemistry|December 9, 2000
Cystic fibrosis transmembrane conductance regulator facilitates ATP release by stimulating a separate ATP release channel for autocrine control of cell volume regulationG M Braunstein, R M Roman, J P Clancy, et al.
Thorax|June 11, 2013
Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infectionJ P Clancy, L Dupont, M W Konstan, et al.
Physical Review Letters|April 29, 2014
Tuning magnetic coupling in Sr2IrO4 thin films with epitaxial strainA Lupascu, J P Clancy, H Gretarsson, et al.
Physical Review Letters|August 29, 2014
Crystal-field splitting and correlation effect on the electronic structure of A2IrO3H Gretarsson, J P Clancy, X Liu, et al.
American Journal of Respiratory and Critical Care Medicine|September 18, 2013
Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator functionS Vamsee Raju, Patricia L Jackson, Clifford A Courville, et al.
Human Gene Therapy|May 8, 2001
A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosisF E Ruiz, J P Clancy, M A Perricone, et al.
Frontiers in Immunology|January 27, 2023
Alpha-1 antitrypsin limits neutrophil extracellular trap disruption of airway epithelial barrier functionK M Hudock, M S Collins, M A Imbrogno, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 12, 2020
Building global development strategies for cf therapeutics during a transitional cftr modulator eraN Mayer-Hamblett, S van Koningsbruggen-Rietschel, D P Nichols, et al.
Neurology|December 8, 2006
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe diseaseP S Kishnani, D Corzo, M Nicolino, et al.
The New England Journal of Medicine|November 19, 2010
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutationFrank J Accurso, Steven M Rowe, J P Clancy, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
The Journal of Biological Chemistry|December 9, 2000
Cystic fibrosis transmembrane conductance regulator facilitates ATP release by stimulating a separate ATP release channel for autocrine control of cell volume regulationG M Braunstein, R M Roman, J P Clancy, et al.
Thorax|June 11, 2013
Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infectionJ P Clancy, L Dupont, M W Konstan, et al.
Physical Review Letters|April 29, 2014
Tuning magnetic coupling in Sr2IrO4 thin films with epitaxial strainA Lupascu, J P Clancy, H Gretarsson, et al.
Physical Review Letters|August 29, 2014
Crystal-field splitting and correlation effect on the electronic structure of A2IrO3H Gretarsson, J P Clancy, X Liu, et al.
American Journal of Respiratory and Critical Care Medicine|September 18, 2013
Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator functionS Vamsee Raju, Patricia L Jackson, Clifford A Courville, et al.
Human Gene Therapy|May 8, 2001
A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosisF E Ruiz, J P Clancy, M A Perricone, et al.
Frontiers in Immunology|January 27, 2023
Alpha-1 antitrypsin limits neutrophil extracellular trap disruption of airway epithelial barrier functionK M Hudock, M S Collins, M A Imbrogno, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 12, 2020
Building global development strategies for cf therapeutics during a transitional cftr modulator eraN Mayer-Hamblett, S van Koningsbruggen-Rietschel, D P Nichols, et al.
Neurology|December 8, 2006
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe diseaseP S Kishnani, D Corzo, M Nicolino, et al.
The New England Journal of Medicine|November 19, 2010
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutationFrank J Accurso, Steven M Rowe, J P Clancy, et al.
Pageof 7